Dafrazol 14 tablets

Form: Tablets
Dosage: 20mg
Packaging: 14 capsules for oral use

Active substance :  omeprazole

Form : capsules with gastro-resistant micro pellets

Dosage par capsule :  20 mg

Packaging :  Box with blister of 7 capsules.

14 capsules box (2 blisters) / 28 capsules box (4 blisters)

Target : Adults ,adolescents and  children > 1 y ( ≥ 10 kg)


  • Treatment and prevention of of duodenal / gastric ulcers
  • In combination with appropriate antibiotics, Helicobacter pylori eradication in peptic ulcer disease
  • Treatment and long term management of reflux oesophagitis (GERD)
  • Treatment of Zollinger-Ellison syndrome

Children >1 y and  ≥ 10 kg

  • Treatment of reflux oesophagitis
  • Symptomatic treatment of heartburn and acid regurgitation in gastro-oesophageal reflux disease Children > 4 y and  adolescents

In combination with antibiotics in treatment of duodenal ulcer caused by H. pylori

Adults :

The recommended dose is Dafrazol 20 mg once daily.

In cases of refractory disease the dosage may be increased to two capsules of Dafrazol 20 mg once daily.

In the treatment of ulcers due to Helicobacter pylori infection, an appropriate antibiotic therapy should be added

Children de plus d’un an et d’un poids ≥ 10 kg

10 to 20 kg: 10 mg/day (half the content of a capsule) – max 20 mg/day

+ 20 kg: 20 mg/day (max 40 mg/day)

As from 30 kg : Adult posology

Dafrazol capsules should be taken in the morning, preferably on an empty stomach, and swallowed whole with half a glass of water. The capsules should not be chewed or crunched. For patients with swallowing difficulties and children, the capsules may be opened and the contents swallowed with half a glass of water or after mixing with a slightly acidic food such as fruit juice, applesauce or non-carbonated water. Enteric-coated granules should not be chewed.

Prescription drugs. Please contact your doctor.

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma